SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows: Regulatory and Development Strategy - Clarity ...

Core Insights - The company has signed a licensing and commercialization agreement with Intas Pharmaceuticals Ltd. for the exclusive commercialization rights of BAT2506 (Golimumab) injection in the U.S. market [1] - The company received a milestone payment of $5.4 million from Intas, after deducting $600,000 for corporate income tax, resulting in a net amount of approximately RMB 38.36 million [1] - This payment will enhance the company's cash reserves, supporting future pipeline research and internationalization strategies [1]

Core Viewpoint - Coherus BioSciences is repurchasing approximately $170 million of its outstanding 1.500% Convertible Senior Subordinated Notes due 2026, contingent upon the closing of the divestiture of its UDENYCA franchise to Intas Pharmaceuticals [1][2][4] Group 1: Repurchase Details - The repurchase will occur at a cash price equal to 100% of the principal amount plus accrued interest [1] - After the repurchase, approximately $60 million of Convertible Notes will remain outstanding, which the company plans to repurchase following the divestiture [3] - The majority of the holders of the Convertible Notes have consented to amendments in the Indenture to facilitate the divestiture transaction [4] Group 2: Company Overview - Coherus BioSciences is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a promising pipeline targeting various cancers [5][6] - The company is focused on enhancing immune responses through its immuno-oncology pipeline, which includes multiple antibody candidates [6] - Coherus markets LOQTORZI and UDENYCA, with the latter being a biosimilar of Neulasta, and plans to close the divestiture transaction in early Q2 2025 [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 地舒單抗生物類似藥HLX14（重組抗RANKL全人單克隆抗體注射液） 的生物製品許可申請(BLA)獲美國食品藥品管理局(FDA)受理 C. 市場情況 截至本公告日，於全球上市的地舒單抗注射液包括Amgen Inc. 以不同商品名 獲批用於不同適應症的PROLIA/XGEVA、Daiichi Sankyo Company Limited 的PRALIA、Intas Pharmaceuticals Ltd.的ROZEL等。根據IQVIA CHPA與 IQVIA MIDASTM的資料（IQVIA是全球醫藥健康產業專業信息和戰略諮詢服 務提供商），2023年度，地舒單抗注射液於全球範圍內的銷售額約為68.30億 美元。 本公告由上海復宏漢霖生 ...